Bio-Rad Laboratories, Inc. (BIO) |
| 288.17 8.92 (3.19%) 04-13 16:00 |
| Open: | 277.82 |
| High: | 289.5 |
| Low: | 277.82 |
| Volume: | 102,760 |
| Market Cap: | 7,778(M) |
| PE Ratio: | 10.35 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 338.14 |
| Resistance 1: | 289.50 |
| Pivot price: | 276.20 |
| Support 1: | 270.62 |
| Support 2: | 258.95 |
| 52w High: | 343.12 |
| 52w Low: | 211.43 |
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| EPS | 27.840 |
| Book Value | 276.160 |
| PEG Ratio | 0.00 |
| Gross Profit | 61.131 |
| Profit Margin (%) | 29.42 |
| Operating Margin (%) | 8.87 |
| Return on Assets (ttm) | 1.7 |
| Return on Equity (ttm) | 10.8 |
Mon, 13 Apr 2026
Molecular Omics Market Is Going to Boom | BGI Group • Bio-Rad Laboratories • PerkinElmer - openPR.com
Wed, 08 Apr 2026
The Bull Case For Bio-Rad Laboratories (BIO) Could Change Following Citigroup’s Downgrade To Neutral - simplywall.st
Tue, 07 Apr 2026
Bio-Rad Laboratories (BIO) Downgraded by Citigroup with Lower Pr - GuruFocus
Tue, 07 Apr 2026
Citigroup downgrades Bio-Rad Laboratories (BIO) - MSN
Thu, 26 Mar 2026
Vanguard disaggregates holdings; Bio‑Rad Labs (NYSE: BIO) shows 0 shares - Stock Titan
Wed, 25 Mar 2026
[ARS] BIO-RAD LABORATORIES, INC. SEC Filing - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |